Want to see TSE:INNO full AI Analyst Report?
INNO Stock Chart & Stats
C$7.50
C$0.01(5.26%)
At close: 4:00 PM EST
C$7.50
C$0.01(5.26%)
Day’s Range― - ―
52-Week RangeC$2.50 - C$21.00
Previous CloseN/A
Volume118.77K
Average Volume (3M)920.00
Market Cap
C$11.25M
Enterprise ValueC$4.95M
Total Cash (Recent Filing)C$6.68M
Total Debt (Recent Filing)C$1.42M
Price to Earnings (P/E)―
Beta-0.60
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding4,498,772
10 Day Avg. Volume392
30 Day Avg. Volume920
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.90
Price to Sales (P/S)0.82
P/FCF Ratio45.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginsA sustained gross margin near 90% indicates the company’s products or formulations carry significant per-unit economics. This structural margin advantage gives flexibility to absorb R&D and commercial investments and means, if operating costs are controlled, the business can scale toward durable profitability over multiple quarters.
Moderate Leverage And Asset BaseA relatively low debt-to-equity (~0.27) with meaningful asset and equity base provides financial flexibility. This capital structure reduces near-term refinancing pressure, allowing the company to fund operations or targeted R&D without immediate dilution, supporting execution over the coming 2–6 months.
Niche Product Focus And Proprietary Delivery TechA clear strategic focus on cannabinoid therapeutics and proprietary delivery platforms creates a differentiated product roadmap and potential barriers to entry. This specialization supports durable competitive advantages in formulation IP, regulatory development pathways, and niche market positioning over a medium-term horizon.
Bears Say
Negative Operating & Free Cash FlowReversal to negative operating and free cash flows signals the company is burning cash rather than generating it. Over a 2–6 month horizon this raises funding risk, may require external capital or cost cuts, and constrains the ability to invest consistently in commercialization or R&D without dilutive financing.
Revenue Decline After Prior RampA TTM revenue decline of ~5.4% following several years of rapid growth suggests demand or execution momentum has weakened. Durable growth momentum is critical for scaling margins and absorbing fixed costs; a reversal undermines revenue predictability and increases reliance on non-operational funding to sustain operations.
Persistent Operating Losses And Negative ReturnsDespite very high gross margins, the company remains loss-making with negative operating profit and negative returns on capital. This structural inability to convert gross profit into operating profitability suggests fixed costs or inefficiencies that must be fixed to achieve durable earnings, and continued losses can erode the equity base over time.
InnoCan Pharma News
INNO FAQ
What was InnoCan Pharma’s price range in the past 12 months?
InnoCan Pharma lowest stock price was C$2.50 and its highest was C$21.00 in the past 12 months.
What is InnoCan Pharma’s market cap?
InnoCan Pharma’s market cap is C$11.25M.
When is InnoCan Pharma’s upcoming earnings report date?
InnoCan Pharma’s upcoming earnings report date is Aug 31, 2026 which is in 61 days.
How were InnoCan Pharma’s earnings last quarter?
InnoCan Pharma released its earnings results on May 27, 2026. The company reported -C$0.296 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.296.
Is InnoCan Pharma overvalued?
According to Wall Street analysts InnoCan Pharma’s price is currently Overvalued.
Does InnoCan Pharma pay dividends?
InnoCan Pharma does not currently pay dividends.
What is InnoCan Pharma’s EPS estimate?
InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCan Pharma have?
InnoCan Pharma has 4,498,772 shares outstanding.
What happened to InnoCan Pharma’s price movement after its last earnings report?
InnoCan Pharma reported an EPS of -C$0.296 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.88%.
Which hedge fund is a major shareholder of InnoCan Pharma?
Currently, no hedge funds are holding shares in TSE:INNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InnoCan Pharma
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland, France, and various international markets. The company actively pursues research and development into treatments for conditions such as COVID-19, leveraging CBD delivered via exosomes and liposomes. InnoCan's product line features a range of CBD-infused topical items, including eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Beyond R&D, the corporation is also involved in the marketing and distribution of its proprietary CBD-enhanced pharmaceutical and cosmetic offerings. Established in 2018, InnoCan Pharma Corporation maintains its principal office in Calgary, Canada.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Voyageur Pharmaceuticals
―
Avicanna
―
Options Prices
Currently, No data available
---